1. Home
  2. SPOK vs AVIR Comparison

SPOK vs AVIR Comparison

Compare SPOK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spok Holdings Inc.

SPOK

Spok Holdings Inc.

HOLD

Current Price

$12.94

Market Cap

267.8M

ML Signal

HOLD

Logo Atea Pharmaceuticals Inc.

AVIR

Atea Pharmaceuticals Inc.

HOLD

Current Price

$3.38

Market Cap

266.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPOK
AVIR
Founded
2004
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medicinal Chemicals and Botanical Products
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.8M
266.4M
IPO Year
1992
2020

Fundamental Metrics

Financial Performance
Metric
SPOK
AVIR
Price
$12.94
$3.38
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
175.7K
393.0K
Earning Date
02-25-2026
11-12-2025
Dividend Yield
9.60%
N/A
EPS Growth
12.68
N/A
EPS
0.80
N/A
Revenue
$139,739,000.00
N/A
Revenue This Year
$4.11
N/A
Revenue Next Year
$2.63
N/A
P/E Ratio
$16.27
N/A
Revenue Growth
1.47
N/A
52 Week Low
$12.26
$2.46
52 Week High
$19.31
$4.02

Technical Indicators

Market Signals
Indicator
SPOK
AVIR
Relative Strength Index (RSI) 42.83 52.39
Support Level $12.82 $3.29
Resistance Level $13.36 $3.63
Average True Range (ATR) 0.24 0.13
MACD 0.03 -0.00
Stochastic Oscillator 17.52 43.09

Price Performance

Historical Comparison
SPOK
AVIR

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: